Expert Review of Clinical Pharmacology

Papers
(The H4-Index of Expert Review of Clinical Pharmacology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments177
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion56
Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis43
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed41
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis36
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion30
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis30
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions30
Clinical pharmacology of antiplatelet drugs30
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?30
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome29
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review29
Reducing the risk of death – a possible outcome in COPD patients29
The pharmacotherapeutics of sarcoidosis27
Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy27
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?27
Hugan tablets for the treatment of RUCAM based drug-induced liver injury: a propensity score matching analysis using a nationwide database25
Fetal safety of medications used in treating infertility25
Cannabidiol drug interaction considerations for prescribers and pharmacists25
Amylin analogs for the treatment of obesity without diabetes: present and future21
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial21
0.050007104873657